Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q1 EPS of ($1.75), $1.74 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $88.64 million versus the consensus estimate of $95.87 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.